We could not find any results for:
Make sure your spelling is correct or try broadening your search.
G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer, such as cell lung cancer and breast c... G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer, such as cell lung cancer and breast cancer, and designs them to combine - and enhance - the anti-tumor activity of current therapies. Show more
RESEARCH TRIANGLE PARK, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
- Achieved $14.1 Million in Net Revenue from Sales of COSELAยฎ (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That...
RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Pepper Bio, the worldโs first transomics...
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...
RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1โs Chief Executive Officer Jack...
RESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
RESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.64 | 16.6233766234 | 3.85 | 4.7 | 3.52 | 679821 | 4.03914867 | CS |
4 | -0.09 | -1.96506550218 | 4.58 | 4.895 | 3.52 | 665116 | 4.32538407 | CS |
12 | -0.25 | -5.27426160338 | 4.74 | 4.895 | 2.01 | 1172413 | 3.37519833 | CS |
26 | 2.85 | 173.780487805 | 1.64 | 5 | 1.31 | 1338535 | 3.23824231 | CS |
52 | 1.44 | 47.2131147541 | 3.05 | 5 | 1.08 | 1070094 | 2.84258459 | CS |
156 | -16.77 | -78.8805268109 | 21.26 | 24.12 | 1.08 | 1045832 | 7.72177822 | CS |
260 | -16.54 | -78.6495482644 | 21.03 | 41.8 | 1.08 | 907428 | 11.80492907 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions